Source:http://linkedlifedata.com/resource/pubmed/id/17552365
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2007-6-7
|
| pubmed:abstractText |
We retrospectively analyzed the outcome of high-risk patients with non-small cell lung cancer (NSCLC) treated with nedaplatin (NP) and irinotecan (CPT) combination chemotherapy. Between July 2002 and January 2006, 31 NSCLC patients with multiple high-risk factors were treated with NP at 50 mg/m2 and CPT at 50 mg/m2 on days 1 and 8 every 4 weeks. Among them, the patients had a total of 85 risk factors, including poor performance status (2 or 3) in 27, cardiac or pulmonary failure in 15, symptomatic bone or brain metastasis in 9, and advanced age (> or = 75 years) in 8, as well as other factors. A total of 83 courses of the chemotherapy were administered and 24 patients were able to receive 2 to 4 courses. With regard to toxicities, 7 (8.4%) and 11 courses (13%) were associated with grade 4 neutropenia and grade 3 febrile neutropenia, respectively. One patient suffered acute myocardial infarction. Each of the toxicities was controllable and there were no treatment-related deaths. One patient achieved CR, 13 achieved PR, 14 SD and 3 PD, and the overall response rate was 45.2%. Of 26 patients with stage IIIB or IV, the median survival time was 232 days, the 1-survival rate was 38.5%, and 3 patients survived for more than 3 years. In conclusion, chemotherapy with NP and CPT appears to be safe and highly effective for high-risk patients with NSCLC.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan,
http://linkedlifedata.com/resource/pubmed/chemical/nedaplatin
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1359-4117
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
251-6
|
| pubmed:meshHeading |
pubmed-meshheading:17552365-Adult,
pubmed-meshheading:17552365-Aged,
pubmed-meshheading:17552365-Aged, 80 and over,
pubmed-meshheading:17552365-Antineoplastic Agents,
pubmed-meshheading:17552365-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17552365-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17552365-Camptothecin,
pubmed-meshheading:17552365-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:17552365-Female,
pubmed-meshheading:17552365-Humans,
pubmed-meshheading:17552365-Lung Neoplasms,
pubmed-meshheading:17552365-Male,
pubmed-meshheading:17552365-Middle Aged,
pubmed-meshheading:17552365-Organoplatinum Compounds,
pubmed-meshheading:17552365-Retrospective Studies,
pubmed-meshheading:17552365-Risk Factors,
pubmed-meshheading:17552365-Survival Analysis,
pubmed-meshheading:17552365-Treatment Outcome
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors.
|
| pubmed:affiliation |
Department of Thoracic Oncology, Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Yokohama 241-0815, Japan. foshita@kcch.jp
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|